drugset / Trial / NCT01671956
Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double blind, placebo-controlled, parallel group multi-center study in adult participants with active moderate to severe UC.
Timeline
- Start
- 2015-07-31
- Primary completion
- 2018-08-31
- Completion
- 2018-11-14
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bertilimumab | Monoclonal antibody | 10 mg/kg | Intravenous |